Delving into the Latest Updates on ZX-06 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Contraception

Originator Organization

zabbio Inc

Active Organization-

Inactive Organization

zabbio Inc

Drug Highest PhasePendingEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

IDH1 mutation (mIDH1) occurs in 20-30% of gliomas and is a promising target for the cancer therapy. In this article, a cross docking-based virtual screening was employed to identify seven small molecules for the allosteric site of mIDH1. Compounds ZX01, ZX05 and ZX06 exhibited the potent inhibitory activity and the high selectivity against WT-IDH1, providing a good starting point for the further development of highly selective mIDH1 inhibitors. Importantly, the parallel artificial membrane permeation assay of the blood-brain barrier (PAMPA-BBB) identified ZX06 with a good ability to penetrate BBB. These findings indicate that ZX06 deserves further optimization as a lead compound for the treatment of patients with IDH1 mutated brain cancers.

100 Deals associated with ZX-06

Login to view more data